[Form 4] LeMaitre Vascular, Inc. Insider Trading Activity

Rhea-AI Filing Summary

LeMaitre Vascular, Inc. (LMAT) reporting person Joseph P. Pellegrino Jr., a company director, reported accruals of dividend equivalent rights on 09/04/2025 tied to previously granted restricted stock unit (RSU) and performance share unit (PSU) awards. The filing itemizes seven separate dividend-equivalent accruals that vest proportionately with their underlying awards, referencing grant dates from 12/2/2020 through 12/6/2024. The report shows the reporting person acquired 19.0048 dividend equivalent rights on 09/04/2025, which correspond to 176.2176 shares of common stock economic equivalent following the transactions. The entries are non-cash accruals (price listed as $0) and were certified by signature on 09/08/2025.

Insights

Financial Analyst

TL;DR: Routine insider accrual of dividend-equivalent rights from RSU/PSU awards; no cash transaction or change in control implied.

The filing documents non-cash accruals of dividend equivalent rights tied to prior equity grants, totaling 19.0048 dividend equivalents representing the economic equivalent of 176.2176 common shares. These accruals vest with the underlying RSU/PSU awards and carry a reported price of $0, indicating they are administrative adjustments rather than open-market trades or sales. For investors, this is a compensation-related disclosure with limited direct impact on capitalization or cash flows.

Corporate Governance Expert

TL;DR: Compensation-related disclosure aligns with equity-award mechanics; no governance red flags apparent.

The Form 4 lists dividend equivalent rights that accrued and vest proportionately with RSU and PSU grants dated between 2020 and 2024. The filing identifies the reporting person as a director and shows these are derivative dividend equivalents rather than new option grants or sales. Documentation appears consistent with routine insider reporting obligations under Section 16; there are no indications of insider trading, accelerated vesting, or related-party transactions disclosed in this form.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pellegrino Joseph P JR

(Last) (First) (Middle)

C/O LEMAITRE VASCULAR, INC.

63 SECOND AVENUE

(Street)

BURLINGTON MA 01803

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
LEMAITRE VASCULAR INC [ LMAT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/04/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Dividend Equivalent Rights	(1)	09/04/2025		A		0.7211		(1)	(1)	Common Stock	0.7211	$0	17.1959	D
Dividend Equivalent Rights	(2)	09/04/2025		A		1.3714		(2)	(2)	Common Stock	1.3714	$0	25.3792	D
Dividend Equivalent Rights	(3)	09/04/2025		A		2.7926		(3)	(3)	Common Stock	2.7926	$0	34.8043	D
Dividend Equivalent Rights	(4)	09/04/2025		A		2.7926		(4)	(4)	Common Stock	2.7926	$0	34.1213	D
Dividend Equivalent Rights	(5)	09/04/2025		A		3.5808		(5)	(5)	Common Stock	3.5808	$0	25.8906	D
Dividend Equivalent Rights	(6)	09/04/2025		A		4.2906		(6)	(6)	Common Stock	4.2906	$0	27.2657	D
Dividend Equivalent Rights	(7)	09/04/2025		A		3.4557		(7)	(7)	Common Stock	3.4557	$0	11.5606	D

Explanation of Responses:

1. These dividend equivalent rights accrued on a restricted stock unit award granted on 12/2/2020 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

2. These dividend equivalent rights accrued on a restricted stock unit award granted on 12/11/2021 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

3. These dividend equivalent rights accrued on a restricted stock unit award granted on 12/12/2022 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

4. These dividend equivalent rights accrued on a Performance Share Unit (PSU) award granted on 12/12/2022 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

5. These dividend equivalent rights accrued on a restricted stock unit award granted on 12/8/2023 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

6. These dividend equivalent rights accrued on a Performance Share Unit (PSU) award granted on 12/8/2023 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

7. These dividend equivalent rights accrued on a restricted stock unit award granted on 12/6/2024 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

	/s/ Nathan Ulrich	09/08/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.